Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS (HIK)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 04/25 05:30:00 pm
1220.75 GBp   -0.67%
11:53aHIKMA PHARMACEU : Block listing Interim Review
PU
04/19HIKMA PHARMACEU : Annual Financial Report and Notice of AGM
PU
04/09HIKMA PHARMACEU : launches Epirubicin Hydrocholoride Injection, USP
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : Block listing Interim Review

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2018 | 11:53am CEST

Block Listing Six Monthly Return

Information provided on this form must be typed or printed electronically and provided to an RIS.

LEI: 549300BNS685UXH4JI75

Date:25 April 2018

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ('SOP')

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ('LTIP')

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ('MIP')

&

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ('EIP')

Period of return

From:

1 October 2017

To:

31 March 2018

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 125,277 ordinary shares of 10 pence

MIP: 187,461 ordinary shares of 10 pence

EIP: 80,044 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 800,000 ordinary shares of 10 pence

EIP: 1,200,000 ordinary shares of 10 pence

Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 ordinary shares of 10 pence

LTIP: 18,216 ordinary shares of 10 pence

MIP: 9,345 ordinary shares of 10 pence

EIP: 187,802 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 107,061 ordinary shares of 10 pence

MIP: 978,116 ordinary shares of 10 pence

EIP: 1,092,242 ordinary shares of 10 pence

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Block Listing Six Monthly Return

Stock Option Plan ('SOP')

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2017

-

-

792,700

Blocklisting return on 01/10/17

01/04/2018

-

-

792,700

Blocklisting return on 01/04/18

Block Listing Six Monthly Return

Long Term Incentive Plan ('LTIP')

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2017

-

-

125,277

Blocklisting return on 01/10/17

17/10/2017

0

4,347

120,930

01/12/2017

0

8,984

111,946

04/12/2017

0

4,885

107,061

01/04/2018

-

-

107,061

Blocklisting return on 01/04/18

Block Listing Six Monthly Return

Management Incentive Plan ('MIP')

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2017

-

-

187,461

Blocklisting return on 01/10/17

20/11/2017

0

6,625

180,836

15/12/2017

0

2,720

178,116

12/03/2018

800,000

0

978,116

01/04/2018

-

-

978,116

Blocklisting return on 01/04/18

Block Listing Six Monthly Return

Executive Incentive Plan ('EIP')

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2017

-

-

80,044

Blocklisting return on 01/10/17

27/02/2018

0

10,298

69,746

12/03/2018

1,200,000

0

1,269,746

20/03/2018

0

9,637

1,260,109

20/03/2018

0

26,090

1,234,019

20/03/2018

0

14,530

1,219,489

20/03/2018

0

38,501

1,180,988

20/03/2018

0

68,346

1,112,642

20/03/2018

0

20,400

1,092,242

01/04/2018

-

-

1,092,242

Blocklisting return on 01/04/18

Disclaimer

Hikma Pharmaceuticals plc published this content on 25 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 April 2018 09:52:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS
11:53aHIKMA PHARMACEUTICALS : Block listing Interim Review
PU
04/22HIKMA PHARMACEUTICALS : organizes ' Cancer Network - Middle East and North Afric..
AQ
04/19HIKMA PHARMACEUTICALS : Annual Financial Report and Notice of AGM
PU
04/09HIKMA PHARMACEUTICALS : launches Epirubicin Hydrocholoride Injection, USP
AQ
04/05HIKMA PHARMACEUTICALS : Ex-dividend day for for final dividend
FA
04/04HIKMA PHARMACEUTICALS : launches Palonosetron Hydrochloride Injection
AQ
03/24Globalists buck U.S. index fund trend
RE
03/21VECTURA : posts wider 2017 loss, revenue rise
RE
03/20HIKMA PHARMACEUTICALS : 24.3% Potential Decrease Indicated by Barclays Capital
AQ
03/15HIKMA PHARMACEUTICALS : shares fly despite loss
AQ
More news
News from SeekingAlpha
04/15Longleaf Partners Shareholder Letter Q1 2018 
03/14Hikma Pharmaceuticals' (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnin.. 
03/14Hikma Pharmaceuticals reports FY results 
2017Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2017 Results - Earning.. 
2017Hikma Pharmaceuticals plc. 2017 Q2 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 1 922 M
EBIT 2018 334 M
Net income 2018 191 M
Debt 2018 367 M
Yield 2018 1,80%
P/E ratio 2018 21,74
P/E ratio 2019 18,63
EV / Sales 2018 2,39x
EV / Sales 2019 2,26x
Capitalization 4 224 M
Chart HIKMA PHARMACEUTICALS
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 15,9 $
Spread / Average Target -7,7%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer
Said Samih Taleb Darwazah Executive Chairman
Khalid Walid Hosni Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Surendera Tyagi Chief Scientific Officer, Global Head-R&D
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS8.38%4 224
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398